Change in metabolic parameters and weight in response to risperidone monotherapy in young children with nonpsychotic disorders: a prospective open‐label study
Child and Adolescent Mental Health
Published online on July 15, 2013
Abstract
Background
This study investigates changes in metabolic parameters in prepubertal children after 14–16 weeks of treatment with low‐dose risperidone.
Method
Thirty‐one children (mean age 5.46 ± 1.98 years) were treated with risperidone (0.25–1 mg/day; 0.01–0.07 mg/kg/day). Patients were excluded if they were using any medication other than risperidone or were diagnosed with any medical problem in addition to a non‐psychotic disorder.
Results
Weight (Δ: 2.51 ± 1.94 kg), height (Δ: 0.03 ± 0.04 cm), BMI (Δ: 0.82 ± 1.4), BMI percentile (Δ: 9.72 ± 16.40), BMI z‐score (Δ: 0.33 ± 1.03), triglyceride (Δ: 1.50 ± 23.97 mg/dl), very low density lipoprotein (Δ: 2.99 ± 4.76 mg/dl), insulin (Δ: 3.07 ± 3.38 mIU/ml), and leptin (Δ: 3.02 ± 4.69 ng/ml) were significantly increased (p < .05).
Conclusion
The metabolic side effects of risperidone must be carefully monitored in prepubertal children.